Pneumococcal vaccination in autoimmune rheumatic diseases

Area of Science:

• Immunology
• Infectious Diseases
• Rheumatology

Background:

• Streptococcus pneumoniae causes community-acquired pneumonia with high mortality.
• Patients with autoimmune inflammatory rheumatic diseases (AIRD) face elevated risks of invasive pneumococcal infections.
• Vaccination is a key strategy to mitigate pneumococcal infection risks.

Purpose of the Study:

• To review current guidelines on pneumococcal polysaccharide vaccine 23-valent (PPV-23) and 13-valent conjugate vaccine (PCV-13) for patients with AIRD.
• To provide recommendations for optimal vaccination strategies in this vulnerable population.
• To emphasize the importance of coordinating vaccination with immunosuppressive therapy.

Main Methods:

• Review of international and national vaccine guidelines.
• Analysis of the efficacy and recommendations for PPV-23 and PCV-13 in adult populations.
• Focus on application in patients with autoimmune inflammatory rheumatic diseases (AIRD).

Main Results:

• PCV-13 is recommended for pneumococcal vaccine-naive patients due to its conjugate form.
• PCV-13 is also recommended for patients previously vaccinated with PPV-23.
• Strategic vaccination scheduling is vital for patients with AIRD undergoing immunosuppressive therapy.

Conclusions:

• Vaccination with PPV-23 and PCV-13 is highly important for patients with AIRD.
• PCV-13 is the preferred vaccine for naive patients and recommended for those previously receiving PPV-23.
• Careful planning of vaccination timing is necessary to maximize protection in AIRD patients.